The size of the primary tumour is considered the most important risk factor for the development of metastasis or local recurrence in case of gastrointestinal stromal tumour (GIST). Until now no prospective data are available in the literature about the role of neadjuvant therapy with Imatinib. Between 2009 and 2012 seven patients with a giant GIST > 20 cm underwent a neadjuvant treatment with Imatinib, a radical operation, followed by an adjuvant therapy. These patients were controlled with regard to peri- and postoperative morbidity and disease-free survival. Two patients were considered not resectable and one patient showed liver metastasis at the time of diagnosis. RECIST responses to the neoadjuvant Imatinib were: 2/7 patients with stable disease, 3/7 partial response, 2/7 partial response with down-staging (resectable disease). Because of the following tumour localisations (6 gastric and 1 rectal), six gastrectomies (one en-bloc with left pancreas) and one Holm operation were performed. The patient with simultaneous liver metastasis developed a tumour progression during the follow-up but the others are still tumour free after 2 years. We detected a significant tumour volume regression due to the neadjuvant chemotherapy in cases of GIST > 20 cm (30 %). Our series showed good results for a neadjuvant therapy in cases of giant GIST with the achievement of 100 % R0 resection without a high morbidity rate (in the literature a tumor size > 10 cm and poor localisation is associated to a high risk of R1 - 2 and high morbidity). Peri- and postoperative morbidity are acceptable and the tumour free survival at 2 years is 85 %.
Thieme Onkologie aktuell 212Girotti P et al. Gastrointestinale Stromatumore größer … TumorDiagn u Ther 2014; 35: 212-216 Zusammenfassung ! Beim Gastrointestinalen Stromatumor (GIST) ist die Größe des Primärtumors einer der Hauptrisikofaktoren für eine Metastasierung bzw. das Auftreten von Lokalrezidiven. Bisher gibt es keine prospektiven Daten, die den Wert einer neoadjuvanten Therapie mit Imatinib belegen. Zwischen 2009 und 2012 wurden an unserer Klinik 7 Patienten mit einer GIST-Größe > 20 cm in neoadjuvanter Intention mit Imatinib behandelt, radikal operiert, adjuvant nachbehandelt und in Hinblick auf die peri-/postoperative Morbidität und das tumorfreie Überleben nachkontrolliert. Zwei Patienten waren primär als nicht resektabel eingestuft und ein Patient hatte zum Diagnosezeitpunkt Lebermetastasen. Bei 2/7 war die Tumorerkrankung präoperativ stabil, 3/7 wiesen ein partielles Ansprechen auf und 2/7 hatten ein klares Down-Staging (resektabler Tumor). Durch die Lokalisation des Primärtumors (Magen 6, Rektum 1) erfolgte 6-mal eine Gastrektomie, eine davon en bloc mit einer Pankreaslinksresektion und Resektion von Lebermetastasen und 1-mal eine Rektumexstirpation. Der Patient mit simultanen Lebermetastasen war im Verlauf progredient, alle anderen Patienten sind 2 Jahre postoperativ tumorfrei. Durch die neoadjuvante Therapie ist bei einem GIST > 20 cm eine wesentliche Reduktion der Tumormasse zu erzielen (30 %). Unsere Kasuistik mit GIST > 20 cm belegt die positiven Ergebnisse der neoadjuvanten Therapie mit Imatinib in Hinblick auf eine hohe Rate (100 %) an R0-Resektionen ohne wesentlich erhöhte Morbidität vor allem in Fällen mit allein durch die Tumorgröße ≥ 10 cm und/oder Lokalisation deutlich erhöhtem Risiko für eine R1-/ R2-Resektion. Die perioperative Morbidität ist trotz der Tumormasse gering und das tumorfreie Überleben nach 2 Jahren beträgt 85 %. Abstract !The size of the primary tumour is considered the most important risk factor for the development of metastasis or local recurrence in case of gastrointestinal stromal tumour (GIST). Until now no prospective data are available in the literature about the role of neadjuvant therapy with Imatinib. Between 2009 and 2012 seven patients with a giant GIST > 20 cm underwent a neadjuvant treatment with Imatinib, a radical operation, followed by an adjuvant therapy. These patients were controlled with regard to peri-and postoperative morbidity and disease-free survival. Two patients were considered not resectable and one patient showed liver metastasis at the time of diagnosis. RECIST responses to the neoadjuvant Imatinib were: 2/7 patients with stable disease, 3/7 partial response, 2/7 partial response with down-staging (resectable disease). Because of the following tumour localisations (6 gastric and 1 rectal), six gastrectomies (one en-bloc with left pancreas) and one Holm operation were performed. The patient with simultaneous liver metastasis developed a tumour progression during the follow-up but the others are still tumour free after 2 years. We detected a s...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.